Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax

Infection and Immunity

Volumn 68, Issue 8, 2000, Pages 4549-4558

  Cohen, S ^a   Mendelson, I ^a   Altboum, Z ^a   Kobiler, D ^a   Elhanany, E ^a   Bino, T ^a   Leitner, M ^a   Inbar, I ^a   Rosenberg, H ^a   Gozes, Y ^a   Barak, R ^a   Fisher, M ^a   Kronman, C ^a   Velan, B ^a   Shafferman, A ^a  

^a ISRAEL INSTITUTE FOR BIOLOGICAL RESEARCH   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAX VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE;

AMINO TERMINAL SEQUENCE; ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; FEMALE; GUINEA PIG; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MASS SPECTROMETRY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

ANIMALS; ANTHRAX; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL CAPSULES; BACTERIAL TOXINS; BACTERIAL VACCINES; EVALUATION STUDIES; FEMALE; GENES, BACTERIAL; GUINEA PIGS; MICE; MICE, INBRED ICR; SPORES, BACTERIAL; TIME FACTORS; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 0033914197     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.68.8.4549-4558.2000     Document Type: Article

References (67)

1. Anisimova, T. I., T. V. Pimenov, V. V. Kozhukhov, A. S. Artemiyev, G. M. Sergeeva, V. V. Seroglasov, N. V. Sadovoy, I. D. Kravets, G. D. Elagin, A. V. Maslov, Y. A. Yudnikov, S. V. Surkov, and A. N. Shevlsov. 1996. The development of a dry, combined anthrax vaccine and the evaluation of its efficacy in experiments with laboratory and agricultural animals. Salisbury Med. Bull. 68(Suppl.):122.
2. Baillie, L., A. Moir, and R. Manchee. 1998. The expression of the protective antigen of Bacillus anthracis in Bacillus subtilis. J. Appl. Microbiol. 84:741-746.
3. Band, L., and D. J. Henner. 1984. Bacillus subtilis requires a "stringent" Shine-Dalgarno region for gene expression. DNA 3:17-21.
4. Barnard, J. P., and A. M. Friedlander. 1999. Vaccination against anthrax with attenuated recombinant strains of Bacillus anthracis that produce protective antigen. Infect. Immun. 67:562-567.
5. Beall, F. A., M. J. Taylor, and C. B. Thorne. 1962. Rapid lethal effect in rats of a third component found upon fractionating the toxin of Bacillus anthracis. J. Bacteriol. 83:1274-1280.
6. Belton, F. C., and R. E. Strange. 1954. Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production. Br. J. Exp. Pathol. 35:144-152.
7. Berger, J. A., and A. G. Marr. 1960. Sonic disruption of spores of Bacillus cereus. J. Gen. Microbiol. 22:147-157.
8. Brachman, P. S., H. Gold, S. A. Plotkin, F. R. Fekery, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health 52:632-645.
9. Bron, B. 1990. Plasmids, p. 75-174. In C. R. Harwood and S. M. Cutting (ed.), Molecular biological methods for Bacillus. John Wiley & Sons, Chichester, England.
10. Coulson, N. M., M. Fulop, and R. W. Titball. 1994. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 12:1395-1401.
11. 2/bicarbonate, affects AtxA synthesis. Infect. Immun. 65:2576-2582.
12. Dai, Z., J. C. Sirard, M. Mock, and T. M. Koehler. 1995. The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. Mol. Microbiol. 16:1171-1181.
13. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
14. Escuyer, V., and R. J. Collier. 1991. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:3381-3386.
15. Ezzell, J. W., Jr., and T. G. Abshire. 1988. Immunological analysis of cell-associated antigens of Bacillus anthracis. Infect. Immun. 56:349-356.
16. Farchaus, J. W., W. J. Ribot, S. Jendrek, and S. F. Little. 1998. Fermentation, purification, and characterization of protective antigen from a recombinant, avirulent strain of Bacillus anthracis. Appl. Environ. Microbiol. 64: 982-991.
17. Fish, D. C., B. G. Mahlandt, J. P. Dobbs, and R. E. Lincoln. 1968. Purification and properties of in vitro-produced anthrax toxin components. J. Bacteriol. 95:907-918.
18. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126.
19. Green, B. D., L. Battisti, T. M. Koehler, C. B. Thorne, and B. E. Ivins. 1985. Demonstration of a capsule plasmid in Bacillus anthracis. Infect. Immun. 49:291-297.
20. Grosfeld, H., B. Velan, M. Leitner, S. Cohen, S. Lustig, B.-E. Lachmi, and A. Shafferman. 1989. Semliki Forest virus E2 envelope epitopes induce a non-neutralizing humoral response which protects mice against lethal challenge. J. Virol. 63:3416-3422.
21. Hambleton, P., J. A. Carman, and J. Melting. 1984. Anthrax: the disease in relation to vaccines. Vaccine 2:125-132.
22. Hanna, P. C., D. Acosta, and R. J. Collier. 1993. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA 90:10198-10201.
23. Harwood, C. R., and S. M. Cutting. 1990. Molecular biological methods for Bacillus. John Wiley & Sons, Chichester, England.
24. Hewick, R. M., M. W. Hunkapiller, L. E. Hood, and W. J. Dreyer. 1981. A gas-liquid solid phase peptide and protein sequenator. J. Biol. Chem. 256: 7990-7997.
25. Hoffmaster, A. R., and T. M. Koehler. 1999. Autogenous regulation of the Bacillus anthracis pag operon. J. Bacteriol. 181:4485-4492.
26. Hoffmaster, A. R., and T. M. Koehler. 1999. Control of virulence gene expression in Bacillus anthracis. J. Appl. Microbiol. 87:279-281.
27. Iacono-Connors, L. C., J. Novak, C. Rossi, J. Mangiafico, and T. Ksiazek. 1994. Enzyme-linked immunosorbent assay using a recombinant baculovirus-expressed Bacillus anthracis protective antigen (PA): measurement of human anti-PA antibodies. Clin. Diagn. Lab. Immunol. 1:78-82.
28. Iacono-Connors, L. C., S. L. Welkos, B. E. Ivins, and J. M. Dalrymple. 1991. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immun. 59:1961-1965.
29. Ivins, B., P. Fellows, L. Pitt, J. Estep, J. Farchaus, A. Friedlander, and P. Gibbs. 1995. Experimental anthrax vaccines: efficacy of adjuvants combined with protective antigen against an aerosol Bacillus anthracis spore challenge in guinea pigs. Vaccine 13:1779-1784.
30. Ivins, B. E., and S. L. Welkos. 1986. Cloning and expression of the Bacillus anthracis protective antigen gene in Bacillus subtilis. Infect. Immun. 54:537-542.
31. -) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:303-308.
32. Kallio, P. 1986. The effect of the inverted repeat structure on the production of the cloned Bacillus amyloliquefaciens α-amylase. Eur. J. Biochem. 158: 491-495.
33. Kawamura, F., and R. H. Doi. 1984. Construction of a Bacillus subtilis double mutant deficient in extracellular alkaline and neutral proteases. J. Bacteriol. 160:442-444.
34. Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100.
35. 2 and a trans-acting element activate transcription from one of two promoters. J. Bacteriol. 176:586-595.
36. Leppla, S. H. 1991. The anthrax toxin complex, p. 277-302. In A. Alouf and J. H. Freer (ed.), Source book of bacterial protein toxins, vol. 14. Academic Press, London, England.
37. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166.
38. Leppla, S. H. 1991. Purification and characterization of adenylyl cyclase from Bacillus anthracis. Methods Enzymol. 195:153-168.
39. Little, S. F., and G. B. Knudson. 1986. Comparative efficacy of Bacillus anthracis live spore vaccine and protective antigen vaccine against anthrax in the guinea pig. Infect. Immun. 52:509-512.
40. Little, S. F., S. H. Leppla, and A. M. Friedlander. 1990. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1606-1613.
41. 2-dependent expression of the genetic region for encapsulation from Bacillus anthracis. Mol. Microbiol. 2:371-376.
42. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
43. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39: 371-376.
44. Nilson, B., L. Abrahmsen, and M. Uhlen. 1985. Immobilization and purification of enzymes with staphylococcal protein A gene fusion vectors. EMBO J. 4:1075-1080.
45. 2-terminal signal peptide region of the α-amylase gene from Bacillus amyloliquefaciens. Gene 15:43-51.
46. Pezard, C., P. Berche, and M. Mock. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:3472-3477.
47. Pezard, C., M. Weber, J. C. Sirard, P. Berche, and M. Mock. 1995. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63:1369-1372.
48. Price, L. B., M. Hugh-Jones, P. J. Jackson, and P. Keim. 1999. Genetic diversity in the protective antigen gene of Bacillus anthracis. J. Bacteriol. 181:2358-2362.
49. Puziss, M., L. C. Manning, L. W. Lynch, E. Barclay, I. Abelow, and G. G. Wright. 1963. Large-scale production of protective antigen of Bacillus anthracis anaerobic cultures. Appl. Microbiol. 11:330-334.
50. Quinn, C. P., C. C. Shone, P. C. Turnbull, and J. Melling. 1988. Purification of anthrax-toxin components by high-performance anion-exchange, gel-filtration and hydrophobic-interaction chromatography. Biochem. J. 252:753-758.
51. Quinn, C. P., Y. Singh, K. R. Klimpel, and S. H. Leppla. 1991. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J. Biol. Chem. 266:20124-20130.
52. Reddy, A., L. Battisti, and C. B. Thorne. 1987. Identification of self-transmissible plasmids in four Bacillus thuringiensis subspecies. J. Bacteriol. 169: 5263-5270.
53. Schaeffer, P., J. Millet, and J.-P. Aubert. 1965. Catabolite repression of bacterial sporulation. Proc. Natl. Acad. Sci. USA 54:704-711.
54. Shafferman, A., P. B. Jahrling, R. E. Benveniste, M. G. Lewis, T. J. Phipps, F. Eden-McCutchan, J. Sadoff, G. A. Eddy, and D. S. Burke. 1991. Protection of macaques with a simian immunodeficiency virus envelope peptide vaccine based on conserved human immunodeficiency virus type 1 sequences. Proc. Natl. Acad. Sci. USA 88:7126-7130.
55. Shlvakhov, E. N., and E. Rubinstein. 1994. Human live anthrax vaccine in the former USSR. Vaccine 12:727-730.
56. Singh, Y., V. K. Chaudhary, and S. H. Leppla. 1989. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J. Biol. Chem. 264:19103-19107.
57. Singh, Y., K. R. Klimpel, C. P. Quinn, V. K. Chaudhary, and S. H. Leppla. 1991. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266:15493-15497.
58. Stepanov, A. V., L. I. Marinin, A. P. Pomerantsev, and N. A. Staritsin. 1996. Development of novel vaccines against anthrax in man. J. Biotechnol. 44: 155-160.
59. Turnbull, P. C. 1991. Anthrax vaccines: past, present and future. Vaccine 9:533-539.
60. Turnbull, P. C., M. G. Broster, J. A. Carman, R. J. Manchee, and J. Melling. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:356-363.
61. Uchida, I., K. Hashimoto, and N. Terakado. 1986. Virulence and immunogenicity in experimental animals of Bacillus anthracis strains harboring or lacking 110 MDa and 60 MDa plasmids. J. Gen. Microbiol. 132:557-559.
62. Uchida, I., J. M. Hornung, C. B. Thorne, K. R. Klimpel, and S. H. Leppla. 1993. Cloning and characterization of a gene whose product is a transactivator of anthrax toxin synthesis. J. Bacteriol. 175:5329-5338.
63. Vellanoweth, R. L. 1993. Translation and its regulation, p. 699-711. In J. A. Hoch and R. L. Losick (ed.), Bacillus subtilis and other gram-positive bacteria. Biochemistry, physiology, and molecular genetics. American Society for Microbiology, Washington, D.C.
64. Welkos, S. L., and A. M. Friedlander. 1988. Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microb. Pathog. 5:127-139.
65. Welkos, S. L., J. R. Lowe, F. Eden-McCutchan, M. Vodkin, S. H. Leppla, and J. J. Schmidt. 1988. Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene 69:287-300.
66. Wright, G. G., M. Puziss, and W. B. Neely. 1962. Studies on immunity in anthrax. IX. Effect of variations in cultural conditions on elaboration of protective antigen by strains of Bacillus anthracis. J. Bacteriol. 83:515-522.
67. Wu, X.-C., W. Lee, L. Tran, and S.-L. Wong. 1991. Engineering a Bacillus subtilis expression-secretion system with a strain deficient in six extracellular proteases. J. Bacteriol. 173:4952-4958.